Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma

Clinical Drug Investigation

Volumn 32, Issue 4, 2012, Pages 253-265

  Gerzeli, Simone ^a   Rognoni, Carla ^a   Quaglini, Silvana ^a   Cavallo, Maria Caterina ^b   Cremonesi, Giovanni ^c   Papi, Alberto ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

asthma; beclometasone; economic evaluation; fluticasone propionate; formoterol; salmeterol

Indexed keywords

BECLOMETASONE; BECLOMETASONE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; ITALY; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 84858032756     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11598940-000000000-00000     Document Type: Article

References (23)

1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78
2. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59: 469-78 (Pubitemid 38580764)
3. DalNegroRW,MichelettoC, TosattoR, et al. Costsof asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med 2007; 101: 2511-9
4. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control levels. Pharmacoeconomics 2004; 22: 537-47 (Pubitemid 38858296)
5. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-44 (Pubitemid 39346477)
6. Global Initiative for Asthma. 2009 Update: Workshop Report, Global Strategy for Asthma Management and Prevention [online]. Available from URL: http://www.ginasthma.com [Accessed 2011 Jun 1]
7. Rosenhall L, Borg S, Andersson F, et al. Budesonide/ formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. Int J Clin Pract 2003; 57: 662-7 (Pubitemid 37428200)
8. Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103: 41-9
9. Papi A, Paggiaro P, Nicolini G, et al., ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62 (10): 1182-8 (Pubitemid 47374029)
10. Papi A, Paggiaro PL, Nicolini G, et al. Inhaled Combination Asthma Treatment versus SYmbicort (ICATSY) StudyGroup: beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682-9 (Pubitemid 46554617)
11. Gruppo di lavoro OsMed. L'uso dei farmaci in Italia. Rapporto nazionale anno 2009. Roma: Il Pensiero Scientifico Editore, Luglio, 2010
12. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20: 183-94 (Pubitemid 34454643)
13. De Marco R, Locatelli F, Cazzoletti L, et al. Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respir Res 2005; 16: 6-95
14. Ministero della Sanità . Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariffe. Decreto Ministeriale 22 Luglio 1996
15. Frieri M, Therattil J, Dellavecchia D, et al. A preliminary retrospective treatment and pharmacoeconomic analysis of asthma care provided by allergists, immunologists, and primary care physicians in a teaching hospital. J Asthma 2002; 39: 405-12
16. Andersson F, Stahl E, Barnes PJ et al. Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study. Respir Med 2001; 95: 505-12 (Pubitemid 32622005)
17. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. Pharmacoeconomics 1997; 12: 121-9 (Pubitemid 27323221)
18. Steuten L, Palmer S, Vrijhoef B, et al. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care 2007; 23: 184-91 (Pubitemid 46642726)
19. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012; 106: 205-14
20. Briggs AH, Bousquet J, Wallace MV, et al., on behalf of the GOAL Investigators Group. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006; 61: 531-6
21. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009; 64: 431-8
22. Edelen MO, Burnam MA, Watkins KE, et al. Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression. Med Decis Making 2008; 28: 732-50
23. Van Ganse E, Antonicelli L, Zhang Q, et al. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med 2006; 100: 140-7 (Pubitemid 43033389)